A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib

Liver International

Volumn 36, Issue 8, 2016, Pages 1206-1212

  de la Torre, Manuel A ^a   Buades Mateu, Juan ^a   de la Rosa, Pedro A ^b   Lué, Alberto ^c   Bustamante, Francisco J ^d   Serrano, María T ^c   Testillano, Milagros ^d   Lorente, Sara ^c   Arenas, Juan I ^e   Gil, Cristina ^d   Iñarrairaegui, Mercedes ^a,f   Sangro, Bruno ^a,f  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Instituto de Investigación Sanitaria de Navarra   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^d HOSPITAL DE CRUCES   (Spain)

^e HOSPITAL DONOSTIA   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

hepatocellular carcinoma; portal vein invasion; radioembolization; selective internal radiation therapy; sorafenib

Indexed keywords

SORAFENIB; YTTRIUM 90;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLIZATION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; MALE; MULTIMODALITY CANCER THERAPY; PORTAL VEIN; RADIOEMBOLIZATION; RETROSPECTIVE STUDY; TUMOR INVASION;

EID: 84978864251     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13098     Document Type: Article

References (34)

1. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 [Internet]. Lyon: International Agency for research on Cancer; 2015. [cited 2015 Dec 9]. Available from: http://globocan.iarc.fr/Default.aspx. Accessed 16 April 2015.
2. Sangiovanni A. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126: 1005–14.
3. Fourner A, Llovet J, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245–55.
4. Sangro B. Chemoembolization and radioembolization. Best Pract Res Clin Gastroenterol 2014; 28: 909–19.
5. Iñarrairaegui M.Radioembolization with use of Ytrium9-90 resin microespheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010; 21: 1205–12.
6. Di Marco V, De Vita F, Koskinas J, et al. Sorafenib: from literature to clinical practice. Ann Oncol 2013; 24(Suppl. 2): ii30–7.
7. Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012; 57: 821–9.
8. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908–43.
9. Bruix J, Sherman M. AASLD Practice Guidelines. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–22.
10. Omata M, Lesmana LA, Tateishi R, et al. APASL Guidelines for HCC. Hepatol Int 2010; 4: 439–74.
11. Sangro B, Salem R. Transarterial chemoembolization and radioembolization. Semin Liver Dis 2014; 34: 435–43.
12. Memon K, Kulik L, Lewandowski RJ, et al. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol 2013; 58: 73–80.
13. Sangro B, Carpanese L, Cianni R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Hepatology 2011; 54: 868–78.
14. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52–64.
15. Reig M, Darnell A, Forner A, et al. Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. Semin Liver Dis 2014; 34: 444–55.
16. Gil-Alzugaray B, Chopitea A, Iñarrairaegui M, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 2013; 57: 1078–87.
17. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. SHARP Investigators Study Group. N Engl J Med 2008; 359: 378–90.
18. Yau T, Tang VY, Yao TJ, et al. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014; 146: 1691–700.
19. Kadalayil L, Benini R, Pallan L, et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 2013; 24: 2565–70.
20. Matsui O, Miyayama S, Sanada J, et al. Interventional oncology: new options for interstitial treatments and intravascular approaches: superselective TACE using iodized oil for HCC: rationale, technique and outcome. J Hepatobiliary Pancreat Sci 2010; 17: 407–9.
21. Edeline J, Gilabert M, Garin E, Boucher E, Raoul JL. Yttrium-90 microsphere radioembolization for hepatocellular carcinoma. Liver Cancer 2015; 4: 16–25.
22. Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol 2014; 11: 525–35.
23. Lau WY, Lai EC, Leung TW. Current role of selective internal irradiation with yttrium-90 microspheres in the management of hepatocellular carcinoma: a systematic review. Int J Radiat Oncol Biol Phys 2011; 81: 460–7.
24. Lewandowski RJ, Sato KT, Atassi B, et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 2007; 30: 571–92.
25. Kulik L, Vouche M, Koppe S, et al. Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol 2014; 61: 309–17.
26. Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013; 57: 1826–37.
27. Iavarone M, Cabibbo G, Piscaglia F, et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. SOFIA (SOraFenib Italian Assessment) study group. Hepatology 2011; 54: 2055–63.
28. Iavarone M, Cabibbo G, Biolato M, et al. Predictors of survival of patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology 2015; 62: 784–91.
29. D'Angelo S, Germano D, Zolfino T, et al. Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy. Recenti Prog Med 2015; 106: 217–26.
30. Lencioni R, Kudo M, Ye SL, et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 2014; 68: 609–17.
31. Gramenzi A, Golfieri R, Mosconi C, et al. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. BLOG (Bologna Liver Oncology Group). Liver Int 2015; 35: 1036–47.
32. Kolligs FT, Bilbao JI, Jakobs T, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int 2015; 35: 1715–21.
33. Cheng AL, Guan Z, Chen Z, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer 2012; 48: 1452–65.
34. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25–34.